PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBIT growth above 1.5x AGEN's 5.54%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
27.70%
Operating income growth above 1.5x AGEN's 5.55%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-117.18%
Negative net income growth while AGEN stands at 3.87%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-117.27%
Negative EPS growth while AGEN is at 10.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-117.27%
Negative diluted EPS growth while AGEN is at 10.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.72%
Negative OCF growth while AGEN is at 15.59%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-138.72%
Negative FCF growth while AGEN is at 15.61%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
64.97%
10Y OCF/share CAGR at 50-75% of AGEN's 93.00%. Martin Whitman might fear a structural deficiency in operational efficiency.
64.97%
5Y OCF/share CAGR at 75-90% of AGEN's 81.69%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
27.61%
3Y OCF/share CAGR under 50% of AGEN's 76.47%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
64.19%
Net income/share CAGR at 50-75% of AGEN's 97.02%. Martin Whitman might question if the firm’s product or cost base lags behind.
64.19%
5Y net income/share CAGR at 75-90% of AGEN's 81.03%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
-5.53%
Negative 3Y CAGR while AGEN is 72.38%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.11%
Negative 3Y equity/share growth while AGEN is at 70.66%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.50%
We have a declining book value while AGEN shows 11.96%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.